EPN-17
AN ANALYSIS OF INTRACRANIAL EPENDYMOMAS FOR SURVIVAL AND PROGNOSTIC FACTORS

OBJECTIVE: Ependymal tumors have been diagnosed and treated on basis of the WHO classification of the tumors. However, there is no clear criteria to distinguish between ependymoma and anaplastic ependymoma. The molecular classification has been reported to better than histopathological diagnosis. We analyzed patients with intracranial ependymoma to evaluate survival and prognostic factors. METHODS: We reviewed 48 patients who were diagnosed with ependymomas in our institute from November 1979 to March 2015. Patient age, sex, tumor location, extent of resection, WHO tumor grade, chemotherapy, radiation, progression free survival (PFS), overall survival (OS) were analyzed. Two pathologists assessed all tumors with the histologically scoring system of ependymomas. RESULTS: The WHO grade was relevant to PFS and OS (p = 0.0000645 and p = 0.0216). The 5 years PFS was 0.694 (95% C. I. 0.440-0.850) and 0.167 (95% C.I. 0.041-0.365) in ependymoma and anaplastic ependymomas, respectively. The 5 years OS was 0.868 (95% C.I. 0.644-0.956) and 0.522 (95% C.I. 0.265-0.728). Patient age, sex, tumor location, chemotherapy, radiation and extent of resection were not prognostic factors in our series. CONCLUSIONS: The WHO tumor grade with the histologically scoring system of ependymoma could be clinically survival and prognostic factors in ependymal tumors.